"The ability to have active management to overweight companies that are actually in market producing the drugs and then go down the line to identify those that are in particular phases is powerful," Mazza told CNBC's
Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF, per Roundhill's website as of Friday. The three next largest positions are In the past year, Eli Lilly is up 90%, while Novo Nordisk has gained 68%, as of Friday's market close. Mazza waived concerns that investors have missed out on the rally, noting the weight loss drug industry is still in its"early days."
"The marketplace has plenty of room for growth with other companies coming in, whether they're with more powerful drugs or with things that actually you don't need to have an injectable." 7 tips for developing digital balance, from happiness experts: ‘Find that happy medium where technology is working for you'with AI. They just have a head start," Mazza said." pivoted to focus on diabetes and weight loss drugs a few years ago, were able to get in market and produce results that are remarkable.
الإمارات العربية المتحدة أحدث الأخبار, الإمارات العربية المتحدة عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: Investingcom - 🏆 450. / 53 اقرأ أكثر »
مصدر: CoinDesk - 🏆 291. / 63 اقرأ أكثر »